Abstract 484P
Background
In South Korea, tx for patients (pts) with stage I–IIIA NSCLC is resection, ± systemic tx for stage II and select stage III disease. Osimertinib is a 3rd-generation EGFR-TKI approved as adjuvant tx for resected stage IB–IIIA EGFRm NSCLC, based on ADAURA trial results. To understand rw data prior to adjuvant osimertinib approval, we report EGFR mutation types, tx patterns / outcomes from the South Korean cohort of a global retrospective rw study.
Methods
Medical records of eligible pts (≥18 years [yrs] with resected stage IA–IIIA NSCLC and a positive EGFRm test result, diagnosed between 01 Jan 2014–31 Dec 2017), were assessed from diagnosis (Dx) until last follow-up/death or 31 Dec 2020. Primary objectives included: EGFR mutation type and frequency, tx patterns and overall survival (OS). Site of first recurrence was a secondary objective.
Results
Of 200 pts in South Korea with EGFRm NSCLC, 95 (48%) had Ex19del and 87 (44%) L858R. At Dx, median age was 62 yrs (range: 36–83), 133 pts (67%) were female, 145 (73%) were never smokers; 68 pts (34%) had stage IA disease, 43 (22%) IB, 20 (10%) IIA, 15 (8%) IIB, and 54 (27%) IIIA. In total, 90 pts (45%) received surgery only; 74 (37%) had surgery + adjuvant tx only; 22 (11%) had neoadjuvant + surgery + adjuvant tx; 14 (7%) had salvage/post-recurrence tx (see Table). After median follow-up of 54.7 months from Dx (IQR 44.5–70.1), 5-yr OS was 69% (96% in stage IA, 84% IB, 72% IIA, 73% IIB, 26% IIIA). Of 106 pts who received systemic tx with first recurrence data available, 53 had metastatic recurrence, most commonly in the lung (19/53; 36%) and brain (18/53; 34%).
Conclusions
In this rw study of pts in South Korea with resected EGFRm early-stage NSCLC (Dx 2014–2017), 45% of pts received surgery only and <50% received surgery + adjuvant/neoadjuvant tx; 5-yr OS was suboptimal at 69%. Early Dx and EGFR mutation testing are needed to ensure eligible pts have access to suitable adjuvant tx to improve clinical outcomes. Table: 484P
Treatment received, n (%) | Patients in South Korea (N=200) |
Proportion of patients with surgery only | 90 (45) |
Proportion of patients with neoadjuvant and surgery and adjuvant (within 26 weeks of surgery) treatment* | 22 (11) |
Proportion of patients with surgery and adjuvant (within 26 weeks of surgery) treatment only | 74 (37) |
- Chemotherapy | 73 (99) |
- Targeted therapy | 1 (1) |
- Immunotherapy | 0 |
Proportion of patients with surgery and treatment >26 weeks after surgery (post-recurrence/salvage) | 14 (7) |
- Chemotherapy | 1 (7) |
- Targeted therapy | 14 (100) |
- Immunotherapy | 0 |
Percentages may equal to >100% as patients could have received >1 type of systemic treatment. *No patients received neoadjuvant treatment only.
Clinical trial identification
Editorial acknowledgement
The authors would like to acknowledge Rachel Gater, PhD, of Ashfield MedComms, an Inizio Company, for medical writing support that was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (https://www.ismpp.org/gpp-2022).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
M. Ahn: Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Advisory Board, Honoraria: Bristol Myers Squibb, Merck Sharp & Dohme, Ono Pharmaceutical Co., Ltd., Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Alpha Pharmaceutical, AstraZeneca, Bristol Myers Squibb, Merck Sharpe & Dohme, Ono Pharmaceutical Co. Ltd., Roche, Takeda. J.H. Kang: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Boehringer Ingelheim, AstraZeneca, Novartis, Yuhan Corporation, Ono PHARMA, Genexine; Non-Financial Interests, Personal, Research Funding: Daiichi Sankyo, Boehringer Ingelheim; Non-Financial Interests, Personal, Speaker’s Bureau: MSD, AstraZeneca, Roche, Takeda, Novartis, Daiichi Sankyo, Boehringer Ingelheim, Bristol Myers Squibb, Yuhan Corporation, Bayer. S. Kim: Financial Interests, Personal, Advisory Role, Advisory meeting participation: AstraZeneca; Financial Interests, Personal, Advisory Board, Advisory meeting participation: Amgen, Boehringer Ingelheim, Janssen, Novartis, Takeda, Therapex, Yuhan; Financial Interests, Personal, Other, Lecture: Boehringer Ingelheim; Financial Interests, Personal, Research Funding: Yuhan. D. Kahangire: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. S.P. Nagar, K.L. Davis, M. Jimenez: Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor, RTI Solutions received consulting fees: AstraZeneca. M. Jung: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. M. Sandelin: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. B.C. Cho: Financial Interests, Personal, Advisory Board: KANAPH Therapeutic Inc, Bridgebio therapeutics, Cyrus therapeutics, Guardant Health, Oscotec Inc; Financial Interests, Personal, Advisory Role, Consulting fees: Abion, BeiGene, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus therapeutics, Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli Lilly, GI-Cell, Guardant, HK Inno-N, Imnewrun Biosciences Inc., Janssen, Takeda, MSD, Janssen, Medp; Financial Interests, Personal, Member of Board of Directors: Interpark Bio Convergence Corp., J INTS BIO; Financial Interests, Personal, Other, Founder: DAAN Biotherapeutics; Financial Interests, Personal, Research Grant: MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, GIInnovation, GI-Cell, Abion, AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Champions Onoclogy, CJ bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Jans; Financial Interests, Personal, Royalties: Champions Oncology, Crown Bioscience, Imagen; Financial Interests, Personal, Stocks/Shares: TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp., J INTS BIO. All other authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract